Lucentis achieves visual, anatomic gains in 5 trials

11:32 EDT 22 Aug 2017 | Healio

BOSTON —David Eichenbaum, MD, and colleagues recapped the effects of Lucentis on retinal vein occlusion in takeaway points from five large clinical trials in a poster presented here at the American Society of Retina Specialists meeting.The BRAVO, SHORE and CRUISE trials all studied efficacy and safety of monthly and as-needed ranibizumab (Lucentis, Genentech) treatment for patients with retinal vein occlusion, and the BRIGHTER and CRYSTAL studies looked at efficacy and safety of ranibizumab in patients with retinal vein occlusion with and without macular ischemia.

Original Article: Lucentis achieves visual, anatomic gains in 5 trials


More From BioPortfolio on "Lucentis achieves visual, anatomic gains in 5 trials"

Quick Search


Relevant Topic

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...